▶주메뉴 바로가기
▶본문 바로가기
[THE INVESTOR] Hanmi Pharmaceuticals said on Oct. 30 that its partner Athenex will initiate clinical trials next year on an oncology drug candidate that has utilized its platform. The New York-bas...
[THE INVESTOR] SK Plasma said on Oct. 30 it has started operations at its new Andong plant, raising the company’s production capacity of plasma derivatives by nearly 500 percent. The 31,586-squa...
[THE INVESTOR] JW Pharmaceutical said on Oct. 29 it will invest 2 million pounds (US$2.57 million) in UK biotechnology firm Argonaut Therapeutics which develops epigenetically-acting drugs for the t...
[THE INVESTOR] Korean cosmetics giant Amorepacific said on Oct. 29 that its third-quarter net profit fell 39.8 percent from a year earlier on increased one-off costs. For the three months ended ...
[THE INVESTOR] HanAll Biopharma , a subsidiary of Daewoong Pharmaceutical, said on Oct. 29 it plans to begin phase 3 clinical trials for its anti-TNF ophthalmic solution HM036 in 2019 after complet...
[THE INVESTOR] Korean biotechnology firm Panagene said on Oct. 26 that the country’s health regulator has granted approval for sale of its diagnostics kit for sexually transmitted diseases. The pro...
[THE INVESTOR] Samsung BioLogics said on Oct. 25 that US biotech Biogen has put off its payment date for increasing ownership in their joint venture Samsung Bioepis until Nov. 30 as the regulatory ...
[THE INVESTOR] Reyon Pharmaceutical said on Oct. 25 it has decided to invest 10 billion won (US$8.78 million) in gene therapy developer NeuracleGenetics. Following this, the drug maker will become...
[THE INVESTOR] Celltrion shares continue to slide for the third straight session on Oct. 25 after Singapore‘s sovereign wealth fund Temasek Holdings sold its stake in a block deal worth 895.4 billi...
[THE INVESTOR] Korea’s contract drug maker Samsung BioLogics said on Oct. 23 that it has logged an operating loss of 10.5 billion won (US$9.30 million) in the three months ending Sept. 30, down 48...
[THE INVESTOR] Korean pharmaceutical firm Samsung Bioepis said on Oct. 24 its accumulated sales in the European market reached US$389.1 million in the first three quarters. Samsung Bioepis saw s...
[THE INVESTOR] Korea’s top financial regulator said on Oct. 19 it will hold a meeting later this month to decide on penalizing Samsung BioLogics for alleged accounting fraud. The Securities & Fut...
[THE INVESTOR] Korea’s Seegene said on Oct. 19 it has entered into a partnership agreement with in-vitro diagnostics firm Xi’an Tianlong Science and Technology to make a foray into the Chinese marke...
[THE INVESTOR] Samsung BioLogics said on Oct. 19 that it has been included in Fortune’s Future 50 list of companies with strong future growth prospects. Fortune, in partnership with Boston Consu...
[THE INVESTOR] Korean biopharmaceutical firm Samsung Bioepis said on Oct. 17 it has launched its biosimilar Imraldi in the European market. Imraldi -- a copy of the autoimmune disease drug Humir...
The Investor’s Choice 2018 to crown top startups on Nov. 28
US hedge fund Elliot renews pressure on Hyundai
Ant Financial highlights SMEs, blockchain, global partnerships for further growth
Samsung to offer glimpse of foldable smartphone in Seoul
Game firms gear up to dazzle at G-Star 2018
Able C&C acquires Mefactory for W32b
Korean startup entrepreneur lives brewing dream
SK hynix introduces new DRAM chip
November 15, 2018
